InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,277.51
(
0.80%
)
US TECH 100
18,064.80
(
0.02%
)
Dow Jones
38,686.32
(
1.51%
)
Brent Oil
81.30
(
0.00%
)
Bitcoin
67,701.34
(
0.33%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 830
Posts 119741
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 3714

Tuesday, 12/11/2007 3:09:48 PM

Tuesday, December 11, 2007 3:09:48 PM

Post# of 19309
Scientific Rationale for ATryn in DIC/sepsis (summary version)

[This is a repost of Msg #3715
with fixes for the bad hyperlinks.]


The only approved drug for sepsis is LLY’s Xigris, which has been a commercial flop for the simple reason that it’s not a great drug (#msg-12483101).

Xigris does not address DIC, specifically, but rather sepsis in general. ATryn, on the other hand, is being targeted at DIC within the context of sepsis. I think it’s fair to say that these are two distinct markets. Moreover, a key differentiator of ATryn vs other drugs that have been considered as possible treatments for sepsis is that ATryn is both an anti-inflammatory agent and an anticoagulant (#msg-23010821).

The overall understanding of DIC in sepsis has advanced greatly in the past few years as the 2001 Kybersept data have been thoroughly analyzed for clues as to what went wrong (#msg-20150658). This, in turn, has led to renewed testing of antithrombin in animal models of DIC/sepsis, and the results of this testing have been encouraging.

With a firm scientific grounding from the new preclinical data and an enhanced understanding of the ramifications of Kybersept, it would seem that GTC’s DIC program has a good chance to bear fruit.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up